{
    "clinical_study": {
        "@rank": "149578", 
        "acronym": "PTINCLC", 
        "arm_group": [
            {
                "arm_group_label": "A.Individuation chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "for A.Individuation chemotherapy The patients received the chemotherapy regimens based on ERCC1, RRM1, TS and \u03b2-tubulin expression measured by immunohistochemical staining.\nPatients received carboplatin at AUC(area under curve )=5, gemcitabine 1250 mg/m2 on days 1 and 8, or pemetrexed 500mg/m2, or docetaxel 75 mg/m2 in each 21 day cycle."
            }, 
            {
                "arm_group_label": "B. standard therapy", 
                "arm_group_type": "Experimental", 
                "description": "carboplatin non-individuation and chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "Excision repair cross complementing 1 (ERCC1) ribonucleotide reductase M1 (RRM1) \u3001\u03b2-tubulin\n      (TUB) and thymidylate synthase(TS) are molecular determinants that predict sensitivity or\n      resistance to platinum agents \u3001paclitaxel  gemcitabine and pemetrexed respectively.\n\n      Tailored therapy using these molecular determinants suggested patient benefit in a\n      previously reported phase 2 trial. Here, we designed a study for an individual patient\n      analysis of prospectively accrued patients who were treated with the \"personalized therapy\"\n      approach versus other standard approaches."
        }, 
        "brief_title": "Personalized Therapy in Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lung Cancer", 
            "Carboplatin Adverse Reaction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients who had nonsmall cell lung cancer (NSCLC) performance status of 0/1 were accrued to\n      2 phase 2 clinical trials Trial A (carboplatin and chemotherapy individuation based on\n      sensitivity marker ), Trial B (carboplatin non-individuation or chemotherapy\n      non-individuation ).\n\n      Patients who were treated on Trials B were analyzed as the \"standard therapy\" group.\n      Patients accrued to Trial A were called the \"personalized therapy\" group. Overall survival\n      (OS), disease free survival (DFS) and progression-free survival (PFS) were estimated using\n      the Kaplan-Meier method."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed non-small cell lung cancer\n\n          2. age  from 18 years to 75 years\n\n          3. ECOG Performance Status no more than 2\n\n          4. at least one appraisable lung focus of diameter\u2265 10 mm by lung CT\n\n          5. Haemoglobin \u226510.0 g/dl, Absolute neutrophil count \u2265(ANC) 1.5 x 109/L, platelets \u2265100\n             x 109/L\n\n          6. Total bilirubin \u22641.5 x upper limit of normal (ULN)\n\n          7. ALT and AST < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of\n             liver metastases\n\n          8. Creatinine clearance \u226560ml/min (calculated according to Cockcroft-gault formula)\n\n          9. Informed consent should be obtained before treatment.\n\n        Exclusion Criteria:\n\n          1. Mixed non-adenocarcinoma cell lung cancer histology\n\n          2. Previous treatment for Systemic chemotherapy  or local radiotherapy\n\n          3. Be allergic to chemotherapy drugs\n\n          4. second active primary malignancy or serious concomitant medical disease\n\n          5. difficulties with adequate follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781988", 
            "org_study_id": "GZMC12521", 
            "secondary_id": "PT12521"
        }, 
        "intervention": {
            "arm_group_label": [
                "A.Individuation chemotherapy", 
                "B. standard therapy"
            ], 
            "description": "Drugs are chosen to be used in  the both Arms carboplatin: iv on the first day of each cycle until progressive disease  or unacceptable toxicity or no more than 6 cycles gemcitabine :500 mg/m\u00b2 intravenous (iv) on the first and eighth days of each 21day cycle pemetrexed :1250 mg/m\u00b2 intravenous (iv) on the first day of each cycle until PD or unacceptable toxicity or no more than 6 cycles docetaxel:75 mg/m\u00b2 intravenous (iv) on the first day of each cycle", 
            "intervention_name": "carboplatin, gemcitabine,pemetrexed,docetaxel", 
            "intervention_type": "Drug", 
            "other_name": [
                "Drug: carboplatin", 
                "Other Names:platinum", 
                "Drug: gemcitabine", 
                "Drug: pemetrexed", 
                "Other Names:ALIMTA"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Pemetrexed", 
                "Docetaxel", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "lung cancer", 
            "gemcitabine", 
            "carboplatin", 
            "pemetrexed"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510120"
                }, 
                "name": "The first affiliated hospital of Guangzhou MC"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Clinical Study of Personalized Therapy for Non-small Cell Lung Cancer Based on ERCC1/RRM1/TS/\u03b2-Tubulin Expression", 
        "other_outcome": {
            "description": "From treatment beginning,  the patients will be  followed for up to  5 years.", 
            "measure": "overall survival of  patients", 
            "safety_issue": "Yes", 
            "time_frame": "up to 5 years"
        }, 
        "overall_official": {
            "affiliation": "The first affiliated hospital of Guangzhou MC", 
            "last_name": "Jianxing He, Proressor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "From treatment beginning,Patients will be followed for up to 2 years.", 
            "measure": "progression-free survival of Patients", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781988"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangzhou Medical University", 
            "investigator_full_name": "Heyuwen", 
            "investigator_title": "Yuwen  He, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "After treatment beginning, patients will be followed for up to 4 years.", 
            "measure": "disease-free survival of  patients", 
            "safety_issue": "Yes", 
            "time_frame": "up to  4  years"
        }, 
        "source": "Guangzhou Medical University", 
        "sponsors": {
            "collaborator": {
                "agency": "The First Affiliated Hospital of Guangzhou Medical University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Guangzhou Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2009", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}